Author

Kent Haderslev

OUTCOMES OF CORONAVIRUS DISEASE 2019 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND THE INFLUENCE OF IBD-RELATED MEDICATIONS– A DANISH PROSPECTIVE POPULATION-BASED COHORT STUDY
OUTCOMES OF CORONAVIRUS DISEASE 2019 AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES AND THE INFLUENCE OF IBD-RELATED MEDICATIONS– A DANISH PROSPECTIVE POPULATION-BASED COHORT STUDY

Kent Haderslev  et al.

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Kent Haderslev  et al.

Item 1 - 2 / 2
1